PureTech Health

Co-founder and non-executive director of PureTech, David H. Koch Institute Professor at MIT, and one of the most prolific and cited inventors in medicine, serving on boards including Moderna.

SVP of communications at PureTech directing corporate, brand, internal communications, and investor and media relations since 2016. Previously worked at PR agencies TogoRun and Feinstein Kean Healthcare.

COO and general counsel at PureTech leading strategic, operational, and legal matters since 2021. Previously VP, Corporate Legal Counsel at Anika Therapeutics.

Board observer and R&D Committee chair, Nobel laureate in Physiology or Medicine and David H. Koch Professor of Biology at MIT, and co-founder of multiple life science companies.

Independent non-executive director since 2009 and former president of Pfizer Global Research and Development, serving on several biotech boards including Vedanta Biosciences and Immunome.

Independent non-executive director, pioneer of India's biotech industry, and founder of Biocon, who serves on boards including Infosys and Narayana Health.

Chief accounting officer overseeing accounting, compliance, and finance operations at PureTech since 2023. Previously CFO of Acronis and interim CFO of Wallarm, with over 20 years of finance experience.

Independent non-executive director and Audit Committee member with over 30 years of healthcare experience. Former EVP and Chief Strategy Officer at Cardinal Health and COO of Global R&D at Teva.

CEO and board member of PureTech, previously CEO of Arix Bioscience plc. An experienced leader of UK-listed life science and venture capital companies who began his career as a lawyer at Bird & Bird before joining Touchstone Innovations.

Interim board chair and Audit Committee member at PureTech; CFO, North America for Teva Pharmaceuticals since 2023 and former SVP of Finance at EQRx, with over two decades of experience at Merck.

Fadi Selwan is Senior Vice President, Head of Communications at PureTech Health, where he leads internal and external communications and investor relations for the clinical-stage biotherapeutics company and several of its Founded Entities. He has overseen communications for FDA approvals, IPOs, clinical data readouts, and M&A events, working across sectors including neurology, immunology, oncology, metabolic disorders, and rare disease over a 15-year career spanning in-house and agency roles. Selwan is also a founding producer of Biotech Hangout, a weekly discussion series hosted on X Spaces and available on podcast platforms.

Nishtha Pandit is Interim Chairperson of the Board at PureTech Health plc, where she also chairs the Audit Committee and serves on the Transaction Committee. She is CFO of the U.S. business at Teva Pharmaceuticals, overseeing a portfolio of more than 1,000 products across specialty, biosimilars, and generics generating over $8 billion in annual revenue, with responsibilities spanning investor relations, capital markets strategy, and debt refinancing. Earlier in her career, she spent 22 years at Merck, including roles as CFO of US Oncology and leader of Portfolio Strategy, Operations, and Business Analytics, and later served as SVP of Global Finance at EQRx.

Raju Kucherlapati is a Professor of Genetics at Harvard Medical School. He earned his PhD from the University of Illinois Urbana-Champaign and completed postdoctoral training at Yale University, following degrees earned in India. He was elected to the National Academy of Medicine and served on the Presidential Commission for the Study of Bioethical Issues from 2009 to 2017.